Cargando…

Epigenetically inactivated RASSF1A as a tumor biomarker

RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A...

Descripción completa

Detalles Bibliográficos
Autores principales: Raos, Dora, Ulamec, Monika, Bojanac, Ana Katusic, Bulic-Jakus, Floriana, Jezek, Davor, Sincic, Nino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292865/
https://www.ncbi.nlm.nih.gov/pubmed/33175673
http://dx.doi.org/10.17305/bjbms.2020.5219
_version_ 1783724908866437120
author Raos, Dora
Ulamec, Monika
Bojanac, Ana Katusic
Bulic-Jakus, Floriana
Jezek, Davor
Sincic, Nino
author_facet Raos, Dora
Ulamec, Monika
Bojanac, Ana Katusic
Bulic-Jakus, Floriana
Jezek, Davor
Sincic, Nino
author_sort Raos, Dora
collection PubMed
description RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A was detected in various cancer types and led to significant interest; current research on RASSF1A promoter methylation focuses on its roles as an epigenetic tumor biomarker. Typically, researchers analyzed genomic DNA (gDNA) to measure the amount of RASSF1A promoter methylation. Cell-free DNA (cfDNA) from liquid biopsies is a recent development showing promise as an early cancer diagnostic tool using biomarkers, such as RASSF1A. This review discusses the evidence on aberrantly methylated RASSF1A in gDNA and cfDNA from different cancer types and its utility for early cancer diagnosis, prognosis, and surveillance. We compared methylation frequencies of RASSF1A in gDNA and cfDNA in various cancer types. The weaknesses and strengths of these analyses are discussed. In conclusion, although the importance of RASSSF1A methylation to cancer has been established and is included in several diagnostic panels, its diagnostic utility is still experimental.
format Online
Article
Text
id pubmed-8292865
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-82928652021-08-01 Epigenetically inactivated RASSF1A as a tumor biomarker Raos, Dora Ulamec, Monika Bojanac, Ana Katusic Bulic-Jakus, Floriana Jezek, Davor Sincic, Nino Bosn J Basic Med Sci Review Article RASSF1A, one of the eight isoforms of the RASSF1 gene, is a tumor suppressor gene that influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity, and, most commonly, by promoter hypermethylation. Epigenetic inactivation of RASSF1A was detected in various cancer types and led to significant interest; current research on RASSF1A promoter methylation focuses on its roles as an epigenetic tumor biomarker. Typically, researchers analyzed genomic DNA (gDNA) to measure the amount of RASSF1A promoter methylation. Cell-free DNA (cfDNA) from liquid biopsies is a recent development showing promise as an early cancer diagnostic tool using biomarkers, such as RASSF1A. This review discusses the evidence on aberrantly methylated RASSF1A in gDNA and cfDNA from different cancer types and its utility for early cancer diagnosis, prognosis, and surveillance. We compared methylation frequencies of RASSF1A in gDNA and cfDNA in various cancer types. The weaknesses and strengths of these analyses are discussed. In conclusion, although the importance of RASSSF1A methylation to cancer has been established and is included in several diagnostic panels, its diagnostic utility is still experimental. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2021-08 /pmc/articles/PMC8292865/ /pubmed/33175673 http://dx.doi.org/10.17305/bjbms.2020.5219 Text en Copyright: © The Author(s) (2021) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Review Article
Raos, Dora
Ulamec, Monika
Bojanac, Ana Katusic
Bulic-Jakus, Floriana
Jezek, Davor
Sincic, Nino
Epigenetically inactivated RASSF1A as a tumor biomarker
title Epigenetically inactivated RASSF1A as a tumor biomarker
title_full Epigenetically inactivated RASSF1A as a tumor biomarker
title_fullStr Epigenetically inactivated RASSF1A as a tumor biomarker
title_full_unstemmed Epigenetically inactivated RASSF1A as a tumor biomarker
title_short Epigenetically inactivated RASSF1A as a tumor biomarker
title_sort epigenetically inactivated rassf1a as a tumor biomarker
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292865/
https://www.ncbi.nlm.nih.gov/pubmed/33175673
http://dx.doi.org/10.17305/bjbms.2020.5219
work_keys_str_mv AT raosdora epigeneticallyinactivatedrassf1aasatumorbiomarker
AT ulamecmonika epigeneticallyinactivatedrassf1aasatumorbiomarker
AT bojanacanakatusic epigeneticallyinactivatedrassf1aasatumorbiomarker
AT bulicjakusfloriana epigeneticallyinactivatedrassf1aasatumorbiomarker
AT jezekdavor epigeneticallyinactivatedrassf1aasatumorbiomarker
AT sincicnino epigeneticallyinactivatedrassf1aasatumorbiomarker